Innate Pharma S.A. is a clinical-stage biotechnology company headquartered in Marseille, France, focused on developing immunotherapies for cancer. The company specializes in monoclonal antibodies, antibody-drug conjugates, and multispecific natural killer (NK) cell engagers built on its proprietary ANKET platform. Its pipeline includes lacutamab, an anti-KIR3DL2 antibody for cutaneous T-cell lymphoma; monalizumab, an anti-NKG2A immune checkpoint inhibitor partnered with AstraZeneca (AZN); and IPH4502, a Nectin-4 ADC in Phase 1 development for advanced solid tumors. Because the company generates revenue primarily through collaborations and licensing rather than product sales, investors follow IPHA closely for clinical data readouts, partnership milestones, and cash runway management. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the trailing 30 days, IPHA has fallen approximately 42%, declining from a closing price near $1.57 to roughly $0.91. The move was not gradual: the stock was trading around $1.50 as recently as mid-November before a sharp two-session collapse drove it below the $1.00 threshold.
The quarterly picture is even steeper. Three months ago, in late August, shares traded near $2.26, meaning the stock has lost roughly 59% of its value over that span. The decline reflects a sustained downtrend punctuated by the recent data-driven selloff, with the share price now well below its 52-week high and near the low end of its trading range.
The most significant catalyst behind the recent decline was the presentation of initial Phase 1 dose-escalation data for IPH4502 at the ENA 2026 conference in mid-November. The company reported an encouraging tolerability profile, with stomatitis as the only dose-limiting toxicity and low hematologic toxicity, as well as antitumor activity across tumor types. However, the market responded negatively, with shares falling sharply in the sessions following the data event.
The selling intensified after Leerink downgraded IPHA from Outperform to Market Perform and reduced its price target from $5 to $1. The firm cited concerns about development timeline delays for IPH4502 and intensifying competition in the urothelial cancer treatment landscape. This contrasted with the more bullish stances of BTIG, which maintained a Buy rating with a $9 target, and H.C. Wainwright, which reiterated Buy with a $7 target — leaving a notably wide dispersion of analyst views on the stock's valuation.
The broader multi-month decline reflects a shift in sentiment around the company's pipeline execution and financing profile. During the quarter, Innate Pharma reported its third-quarter 2026 business update with approximately €96.8 million in cash, and outlined that lacutamab, partnered with Sobi, is progressing toward first patient dosing in the Phase 3 TELLOMAK-3 trial in the first quarter of 2027. The company also updated the timing of the AstraZeneca-led PACIFIC-9 Phase 3 readout to the first half of 2027, pushing a key catalyst further out. Combined with the IPH4502 data and downgrade, these timeline shifts weighed on the stock, as investors reassessed near-term catalysts against the company's cash position and the competitive dynamics in ADC and urothelial cancer markets.
Looking ahead, the most important factors for IPHA include the progression of the lacutamab Phase 3 TELLOMAK-3 trial toward first patient dosing in early 2027, the PACIFIC-9 Phase 3 readout now expected in the first half of 2027, and any additional IPH4502 data or development updates. Investors will also monitor cash runway relative to operating expenses, potential partnership or financing activity, and shifts in analyst coverage given the current wide range of price targets. Competitive developments in the ADC and urothelial cancer spaces, along with broader biotech sector sentiment, are likely to remain key influences on the stock's direction. One thing that stands out is how these timelines could shape near-term moves.
In my own analysis, I often turn to Tickeron’s Trending AI Robots to get a sense of how automated strategies are performing across similar biotech names. The page highlights top bots that have shown strength lately, allowing users to review different trading styles, timeframes, and metrics. It serves as a useful complement when evaluating momentum in volatile names like IPHA, especially when cross-checking against fundamental catalysts. This resource has helped me spot patterns that align with my risk parameters without replacing deeper research.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.
The 50-day moving average for IPHA moved below the 200-day moving average on November 05, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IPHA as a result. In 98 of 113 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for IPHA turned negative on November 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 44 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IPHA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for IPHA entered a downward trend on November 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where IPHA advanced for three days, in 148 of 199 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
IPHA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 17 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-3.971) is normal, around the industry mean (3.596). P/E Ratio (-2.824) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (55.556) is also within normal values, averaging (443.347).
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. IPHA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IPHA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a biopharmaceutical company, which focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment
Industry Biotechnology